• You are a healthy male or female.
• You are between 22 and 65 years old.
• Your weight is at least 50.0 kg and at most 110.0 kg and your Body Mass Index (BMI) is between 18.0 and 30.0 kg/m2. 
• Both non-smokers and light smokers or occasional smokers are allowed to participate in this clinical trial (at most 5 cigarettes daily). During your stay in our research facility you are not allowed to smoke.

Note: 

• You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first compound administration in this clinical trial (counting from the follow-up).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht. For part B, there is a second screening visit for the DEXA scan. During the phone screening phase, it will be discussed where this takes place.  

As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:

• You are using continuous hormonal contraception (the pill or a hormonal IUD) in combination with a condom, cervical cap, or diaphragm used by your male partner;
• You have passed the menopause (no periods for at least 12 months);
• You have been sterilized (ovariectomy).

As a male you can only participate if you meet one of the following conditions:

• You are using a condom in combination with an additional contraception method used by your female partner;
• You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
• You are not sexually active according to your lifestyle;
• You are only sexually active with a partner of the same sex.

Part A: The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 9 days (8 nights), followed by 8 short visits. The follow-up will be during the final short visit.

Part B: The trial consists of 4 periods in the research facility in Groningen (location van Swietenlaan 6). The first period is a stay of 12 days (11 nights). The second and third periods are both 3 days (2 nights) stays. The fourth period is a stay of 7 days (6 nights). There is 1 short visit between the second and third period and between the third and fourth period. After the fourth period, 8 short visits will follow. The follow-up will be during the final short visit. As part of the screening for this part, there is also a separate visit for a DEXA-scan. There is also a follow-up DEXA-scan at or near the final study visit.

Note: You must be available for all dates to be able to participate in this clinical trial.